Latest News
- Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented
August 30, 2018 - Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
July 19, 2018
Latest Presentations
MP Corporate Presentation
August 30, 2018
MP 1H 2018 presentation
August 30, 2018
Products
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase III trials.
We tailor each DARPin® therapy to target single or multiple disease pathways responsible for serious and complex diseases, all in a single medicine.
